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 2 
Abstract 1 
Chronic diabetic foot ulcers are frequently colonised and infected by 2 
polymicrobial biofilms that ultimately prevents healing. In this study, we aimed 3 
to create a novel in vitro inter-kingdom wound biofilm model on complex 4 
hydrogel-based cellulose substrates to test commonly used topical wound 5 
treatments. Inter-kingdom triadic biofilms composed of Candida albicans, 6 
Pseudomonas aeruginosa, and Staphylococcus aureus were shown to be 7 
quantitatively greater in this model compared to a simple substrate when 8 
assessed by conventional culture, metabolic dye and live dead qPCR. These 9 
biofilms were both structurally complex and compositionally dynamic in 10 
response to topical therapy, so when treated with either chlorhexidine or 11 
povidone iodine principal component analysis revealed that the 3-D cellulose 12 
model was minimally impacted compared to the simple substrate model. This 13 
study highlights the importance of biofilm substrate and inclusion of relevant 14 
polymicrobial and inter-kingdom components, as these impact penetration and 15 
efficacy of topical antiseptics.  16 
  17 
 3 
Background 1 
Chronic wounds are associated with unacceptably high morbidity and mortality 2 
rates, in addition to being a significant economic burden to the National Health 3 
Service (NHS) in the UK. It is estimated that the NHS spends in the region of 4 
£900 million per year on diabetic foot ulcer treatments and resultant 5 
amputations (Hex et al. 2012). Infection risk is one of the overriding factors 6 
driving these costs and complications, and the capacity of endogenous and 7 
exogenous microorganisms to form complex biofilms within these 8 
compromised skin environments hinders chemotherapeutic management (Alavi 9 
et al. 2014).  10 
 11 
Pathogenic biofilms are frequently associated with chronic wounds (James et 12 
al. 2008, Neut et al. 2011). These structures complicate treatment strategies 13 
due to enhanced adaptive resistance profiles, primarily driven by the physical 14 
composition, including the production of extracellular matrix (ECM) that 15 
prevents diffusion of antimicrobials into the biofilm (Davies 2003, Pozo and 16 
Patel 2007, Ramage et al. 2012a). ECM-associated degradative enzymes, 17 
hypermutability, and persister cells, are just a few examples of how these 18 
complex communities survive and adapt to antimicrobial challenge (Davies 19 
2003, Høiby et al. 2010, Pozo and Patel 2007, Ramage, et al. 2012a). 20 
Complicating chemotherapeutic intervention even further is the polymicrobial 21 
nature of the biofilms found in diabetic foot ulcers (Smith et al. 2016). Moreover, 22 
increasing evidence that yeasts and moulds play important contributory roles in 23 
exacerbating infections suggests inter-kingdom biofilms deserve consideration 24 
(Peters et al. 2012). 25 
 26 
S. aureus and P. aeruginosa are the two most frequently isolated bacterial 27 
species from such chronic and difficult-to-treat biofilm infections (Citron et al. 28 
2007, Hartemann‐Heurtier et al. 2004, MacDonald et al. 2002). They are 29 
often co-isolated and are associated geographically within the wound site 30 
(Fazli et al. 2009). In contrast to bacteria, despite reports their importance, the 31 
role of pathogenic fungi in wound biofilms, are relatively under-investigated and 32 
underappreciated clinical entities (Appelgren et al. 2002, Dowd et al. 2011, 33 
 4 
MacDonald, et al. 2002, Santucci et al. 2003, Sun 2010, Weinstein and 1 
Mayhall 2003). Candida species are the primary fungal pathogen isolated from 2 
these infections, although this organism rarely colonises healthy intact skin 3 
(Grice and Segre 2011). Several models have been described in recent years 4 
that have examined these paradigm nosocomial pathogens in triadic systems 5 
(Hoekstra et al. 2016, Kart et al. 2014). Though a caveat to the utility and 6 
translation of these models is the basic 2-dimensional nature of the substrates 7 
used, which are not at all representative of a wound environment (Hill et al. 8 
2010, Hoekstra, et al. 2016, Kart, et al. 2014). The development of cellulose 9 
matrix based models supported by hydrogels that better mimic the consistency 10 
of the wound surface enables biofilms to form in a 3-dimensional matrix. Using 11 
either poloxamer, collagen, or agarose hydrogel, a complex hydrated structure 12 
is formed which induces the development of the biofilm phenotype (Clutterbuck 13 
et al. 2007, Harrison et al. 2015, Percival et al. 2007, Strathmann et al. 2000). 14 
The main applicability and translation usefulness of these model systems lies 15 
in their utility in the development and testing of antimicrobial anti-biofilm 16 
molecules. To date, these models have tended to focus on mono-species 17 
biofilms.   18 
 19 
Systemic antibiotics are commonly used to treat chronic wounds, yet there is 20 
controversy over their usage and rising concerns over the development of 21 
antimicrobial resistant organisms (Atiyeh et al. 2009, O'meara et al. 2001). 22 
Topical wound washes and ointments are often recommended as an 23 
alternative to, or in combination with, systemic treatment (Atiyeh, et al. 2009, 24 
Snell et al. 2013). Chlorhexidine (CHX) and povidone iodine (PVP-I) are two of 25 
the most commonly used clinically due to their high levels of biocidal activity 26 
(Atiyeh, et al. 2009, O'meara, et al. 2001).  27 
 28 
The aims of the present study were therefore to develop a polymicrobial inter-29 
kingdom in vitro biofilm model on complex substrates that can be used to test 30 
clinically relevant antimicrobial therapeutics. Here we show for the first time the 31 
use of a novel biofilm substrate that can be adapted to represent a wide variety 32 
of wound infection biofilms, and its application for chronic wound biofilm 33 
research.  34 
 5 
Methods 1 
Culture conditions and standardisation 2 
A selection of characterised laboratory strains were used in this study, 3 
including the bacteria P. aeruginosa PA14 (Rahme et al. 1995), S. aureus 4 
Newman’s strain (Duthie and Lorenz 1952) and the yeast Candida albicans 5 
SC5314 (Fonzi and Irwin 1993). Both bacteria were grown and maintained at 6 
37°C on Luria agar (Sigma-Aldrich, Dorset, UK), while C. albicans was grown 7 
and maintained at 30°C on Sabouraud dextrose agar (SAB [Sigma-Aldrich, 8 
Dorset, UK]). All isolates were stored indefinitely in Microbank® vials (Pro-Lab 9 
Diagnostics, Cheshire, UK) at -80°C.  10 
Overnight broths of P. aeruginosa and S. aureus were prepared in 10 mL Luria 11 
broth ([LB] Sigma-Aldrich, Dorset, UK) at 37°C and C. albicans was 12 
propagated in 10 mL yeast peptone dextrose broth (YPD [Sigma-Aldrich, 13 
Dorset, UK]) at 30°C at 150 rpm. Overnight cultures were washed twice by 14 
centrifugation (1600 x g) and resuspended in 10 mL phosphate buffered saline 15 
(PBS). All cultures were standardised and adjusted to 1 × 108 cells/mL, using 16 
optical density at 590 nm for bacterial strains and a haemocytometer for C. 17 
albicans.  18 
 19 
Hydrogel preparation 20 
Hydrogels were composed of 10% 3-sulfopropyl acrylate potassium salt, 0.95% 21 
v/v poly(ethylene glycol) deacrylate (PEG), 0.01% v/v 1- hydroxycyclohexyl 22 
phenyl ketone, with the addition of 50% heat-inactivated horse serum ([HS] 23 
Thermo Fisher Scientific, Loughborough, UK) in sterile water to the final 24 
volume. To a 12-well flat-bottomed microtiter plates (Corning Incorporated, NY, 25 
USA), 2 mL of hydrogel was added to each well before being polymerised 26 
under a 366 nm ultraviolet (UV) Lamp (Camag, Hungerford, UK) for 30 min 27 
within a class II laminar flow hood. These polymerised hydrogels were then 28 
stored at 4°C until required, for up to one week. 29 
 6 
Biofilm development and antimicrobial therapy 1 
All organisms were standardised to a final working concentration of 1 × 106 2 
cells/mL in 50% v/v HS (Life Technologies, Paisley, UK) for biofilm 3 
development. For viability and biomass assays (described below), 200 µL of 4 
single species and triadic species suspensions were added to 96-well flat-5 
bottomed microtiter plates (Corning Incorporated, NY, USA). For quantitative 6 
polymerase chain reaction (qPCR) and viable cell counting, 500 µL of cultures 7 
were added to Thermanox™ coverslips (13 mm diameter, Fisher Scientific) 8 
contained within 24 well plates (Corning, NY, USA). Biofilms were incubated at 9 
37°C for 24 h to develop. All procedures were carried out in a class II laminar 10 
flow hood. For biofilm development on hydrogels, organisms were 11 
standardised to a 1 × 106 cells/mL in PBS and added to sections of cellulose 12 
matrix (1.25 cm²) (IPS Converters, Oldham, UK). Following initial incubation at 13 
37°C with agitation for 2 h, the matrix was then placed on top of the hydrogel 14 
surface and incubated at 37°C for 24 h. Negative controls containing no 15 
inoculum were also included. All testing was carried out in triplicate, on three 16 
separate occasions. Following biofilm development, cells were washed twice 17 
with PBS to remove any non-adherent cells before treatment with 10% w/v 18 
PVP-I (Sigma) or 0.05% v/v CHX (Sigma) for a further 24 h at 37°C. Untreated 19 
controls were also included.  20 
 21 
Assessment of treatment using conventional quantitative culture 22 
To assess the viability of the organisms contained within the biofilm, viable cell 23 
counting was performed. Following treatment, biofilms were sonicated in 1 mL 24 
PBS, from Thermanox™ coverslips or hydrogel cellulose matrix at 35 kHz for 25 
10 min to remove the biomass, as described previously (Ramage et al. 2012b), 26 
prior to the Miles and Misra technique (Miles et al. 1938). Decimal serial 27 
dilutions were plated on LB and SAB agar, which were incubated at 37°C and 28 
30°C, respectively for 72 h for Thermanox™ coverslips, and 48 h for hydrogel. 29 
The number of colonies were counted and represented as total bacteria and 30 
total yeast colony forming units (CFU) per mL.  31 
 32 
 7 
Assessment of treatments using quantitative viability assays 1 
Following treatment, biofilms were washed twice with PBS before biofilm 2 
viability and biomass were quantified. Viability was assessed by the 3 
AlamarBlue® assay (Invitrogen, Paisley, UK), as per manufacturer’s 4 
instructions (Kirchner et al. 2012). Absorbance was measured 5 
spectrophotometrically at 570 nm and the reference wavelength at 600 nm 6 
(FluoStar Omega, BMG Labtech). All assays were performed in triplicate, on 7 
three separate occasions. 8 
 9 
Assessment of treatment using live/dead quantitative PCR 10 
Viability based qPCR, a technique shown to differentiate between viable and 11 
dead cells (Alvarez et al. 2013, Sanchez et al. 2013, Sanchez et al. 2014, 12 
Sherry et al. 2016), was used to assess the composition and viability of the 13 
biofilms at a molecular level. Samples were prepared as previously described 14 
by our group using propidium monoazide (PMA), a DNA intercalating dye, 15 
which prevents DNA from cells with compromised membranes from being 16 
detected by PCR (Sherry, et al. 2016). Briefly, biofilms were sonicated from 17 
Thermanox™ coverslips or cellulose matrix, 50 μM of PMA was added to each 18 
sample before incubation in the dark for 10 min to allow dye uptake. To permit 19 
binding of the PMA, samples were exposed to a 650 W halogen light for 5 min. 20 
DNA was then extracted using the QIAamp DNA mini kit, as per 21 
manufacturer’s instructions (Qiagen, Crawley, UK). Controls containing no 22 
PMA were also included for each sample to determine total biomass.  23 
Following DNA extraction, qPCR was used to enumerate both the live and total 24 
cells of each species remaining in the biofilm following each treatment. In brief, 25 
1 μL of extracted DNA was added to a mastermix which contained 10 μL Fast 26 
SYBR® Green Master Mix (Life Technologies, Paisley, UK), 7 μL water and 1 27 
μL of 10 μM forward and reverse primers for each bacterial or fungal species. 28 
Primer sequences are shown in Table 1. The thermal profile of 95°C for 20 s 29 
followed by 40 cycles of 3 s at 95°C, and 30 s at 60°C was used in this study. 30 
Three independent replicates for each treatment were analysed in duplicate 31 
 8 
using Step One Real-Time PCR system and software (Life Technologies, 1 
Paisley, UK). Samples were quantified to calculate the colony forming 2 
equivalent (CFE) based upon a standard curve per reaction performed.  3 
 4 
Scanning electron microscopy 5 
Biofilms were grown on Thermanox™ coverslips or hydrogel cellulose matrix 6 
and treated, as previously described. Biofilms were washed twice with PBS, 7 
before being fixed in 2% para-formaldehyde, 2% glutaraldehyde, 0.15M 8 
sodium cacodylate, and 0.15% w/v alcian blue, at pH 7.4, and prepared for 9 
SEM as previously described (Erlandsen et al. 2004). The specimens were 10 
sputter-coated with gold and viewed under a JEOL JSM-6400 scanning 11 
electron microscope. 12 
 13 
Statistical analysis 14 
Graph production, data distribution and statistical analysis were performed 15 
using GraphPad Prism (version 6; La Jolla, CA, USA). Unpaired t-tests were 16 
used to establish significant differences between treatments and substrate 17 
types for viability assay scores and CFEs. Percentage viability scores were log 18 
transformed before statistical analysis took place. For conventional quantitative 19 
culture, Mann-Whitney test was used. Statistical significance was achieved if 20 
P<0.05. Next, viable composition datasets were reduced by log2 transformation 21 
so as to carry out principal component analysis (PCA) using PAST software 22 
(Hammer O 2001). A scree plot was used to determine how many components 23 
emerged. To determine if statistically distinct clusters formed on the PCA plots, 24 
new variables were created for each principle component by using the factor 25 
loadings as regression coefficients, producing a score for each sample. These 26 
scores were then used as outcome variables to compare between groups 27 
using an unpaired t-test. 28 
29 
 9 
Results 1 
Standard 2-D biofilm models show antibacterial agent efficacy in mono-2 
species, while triadic biofilms support some resistance 3 
Firstly, we wanted to establish a baseline using a typical substrate used for in 4 
vitro biofilm studies, i.e. a 2-D polystyrene model. Here we tested two key 5 
topical agents using conventional culture, and based upon this methodology 6 
PVP-I was shown to be the most effective treatment, completely eradicating 7 
the bacterial and yeast biofilm burden of all mono-cultures (P<0.0001) (Figure 8 
1A). In addition, CHX was equally active against P. aeruginosa mono-culture 9 
biofilms and bacteria in the triadic species biofilms, significantly reducing total 10 
bacterial counts by >6 log10 (Figures 1A and 1B). S. aureus and C. albicans 11 
mono-species biofilms were also reduced by CHX treatment (Figure 1A), but 12 
only by >2 log10 (P<0.05, P<0.001, respectively). However, in the 2-D triadic 13 
model yeast counts were completely unaffected (Figure 1B). 14 
Using soluble metabolic dyes (Figure 1C), in the 2-D model C. albicans and P. 15 
aeruginosa mono-culture viability was significantly reduced by both PVP-I and 16 
CHX (P<0.0001). CHX was able to significantly inhibit S. aureus biofilms 17 
(P<0.05), but PVP-I showed no significant reduction. In contrast, in the triadic 18 
culture both CHX and PVP-I caused significant decreases in viability 19 
(P<0.0001).  20 
 21 
Molecular analysis reveals reservoirs of viable cells remain after 22 
treatment of 2-D mono-species and triadic biofilms 23 
The techniques described above are subjective in terms of species-specific 24 
quantification, so given these limitations we decided to employ a molecular 25 
approach, enabling determination of the precise viable composition of biofilms 26 
following active exposure. Despite culture and metabolic evaluation showing a 27 
significant reduction in the viability of all biofilms, viable quantitative analysis by 28 
qPCR revealed a significant number of cells are retained within each biofilm 29 
 10 
(Figure 2 and 3). Molecular analysis consistently showed higher reductions 1 
with PVP-I compared to CHX treatment in both substrates tested.  2 
C. albicans mono-species total cell count was significantly reduced with both 3 
PVP-I (P<0.0001) and CHX (P<0.001) treatment (Figure 2A). The number of 4 
live cells remaining within those treated biofilms was 13% (P<0.0001) and 23% 5 
(P<0.01), respectively. S. aureus mono-species total cell count was also 6 
significantly reduced (88.5%) with PVP-I (P<0.0001), with only 2% live cells 7 
remaining (P<0.0001) (Figure 2B). CHX treatment, however, showed no 8 
difference to the control for both total and live cells (P>0.05). P. aeruginosa 9 
mono-species biofilms were also affected by the two treatments (Figure 2C). P. 10 
aeruginosa mono-species total cells were significantly reduced by PVP-I (77%, 11 
P<0.01), and live cells reduced by 98% (P<0.05). CHX treatment appeared to 12 
cause a significant increase in total cell count (P<0.01), though a slight 13 
decrease in live cells (P>0.05).   14 
The triadic species biofilms were again more effectively treated by PVP-I 15 
compared to CHX (Figure 3). The total cell count on the 2-D model was 16 
significantly reduced by PVP-I (92%, P<0.0001; Figure 3B). Live cells were 17 
similarly reduced compared to untreated biofilms (98%, P<0.001; Figure 3A). 18 
CHX caused a significant increase in total cells, rising by ~2.5 times 19 
(P<0.0001), whereas live cells marginally decreased (20%, P>0.05; Figure 3C). 20 
SEM analysis was used to analyse the biofilm architecture ± treatment (Figure 21 
3). In the 2-D model C. albicans was mainly hyphae, acting as a scaffold to 22 
which the bacteria tended to co-aggregate upon (see insert magnification). The 23 
cell density within the biofilm was reduced by both treatments, although more 24 
so with PVP-I. 25 
 26 
3-D substrates support culturably greater quantities of mono-species and 27 
triadic biofilm cells with enhanced resistance to CHX and PVP-I 28 
Using conventional culture, the 3-D cellulose matrix model, with PVP-I 29 
treatment (Figure 4A) significantly reduced C. albicans, S. aureus, and P. 30 
 11 
aeruginosa monocultures (P<0.0001), whereas CHX was ineffective for both C. 1 
albicans and P. aeruginosa (P>0.05). S. aureus, however, was significantly 2 
decreased by CHX (P<0.0001; Figure 4A). In the triadic hydrogel model, 3 
yeasts and bacteria were significantly reduced by PVP-I (P<0.0001), but not 4 
CHX (P>0.05; Figure 4B). The metabolic assays confirmed these results 5 
(Figure 4C), with both C. albicans and S. aureus monocultures were 6 
significantly reduced by the two treatments (P<0.0001). P. aeruginosa and 7 
triadic cellulose matrix biofilms, although both significantly reduced with PVP-I 8 
treatment (P<0.0001), were seemingly unaffected by CHX treatment, (P>0.05). 9 
 10 
3-D substrates support greater total and viable quantities of mono-and 11 
triadic species biofilm cells with enhanced resistance to CHX and PVP-I 12 
Overall, the treatments on 3-D cellulose matrix mono-species biofilms showed 13 
similar efficacy patterns to the 2-D model, although, 3-D cellulose matrix 14 
models generally had higher numbers of total and viable cells (P<0.05) (Figure 15 
5). C. albicans mono-culture total cell count was reduced by 72% by PVP-I 16 
(P<0.01), whereas CHX was less effective with a 28% reduction (P>0.05) 17 
(Figure 5A). The live cell count within these biofilms was significantly reduced 18 
by 98% and 61% after PVP-I (P<0.001) and CHX treatment (P<0.05), 19 
respectively. Both total and live cell counts for S. aureus were reduced by 20 
approximately 88% by PVP-I (P<0.001) and 98% (P<0.05), respectively 21 
(Figure 5B). Treatment with CHX was ineffective for total and live cells 22 
(P>0.05). CHX reduced P. aeruginosa total cells by only 15%, and viable cells 23 
were unaffected (P>0.05) (Figure 5C). PVP-I, however, was significantly 24 
effective reducing total cell count by 84% (P<0.001) and live cell count by 95% 25 
(P<0.001).  26 
The triadic 3-D model showed a total cell count reduction by 94% with PVP-I 27 
treatment (P>0.05; Figure 6B), and 70% with CHX (P>0.05; Figure 6C). Viable 28 
cell counts were reduced further by PVP-I (97%, P<0.001), whilst CHX was 29 
less effective (22%, P>0.05). 30 
 12 
Based the SEM images, it can be clearly shown that there is an increased cell 1 
number on the 3-D substrates, irrespective of treatment. The fibrous nature of 2 
the cellulose matrix creates a greater surface area. Interestingly, in the 3-D 3 
model C. albicans is observed mainly as yeast cells, which is reflected in the 4 
viable cell numbers reported above. However, on the 3-D substrate the 5 
dominant morphotype was suggestive of P. aeruginosa.  6 
 7 
Statistical analysis reveals significant differences between treatments 8 
and biofilm substrates 9 
Conventional culture and viability assays revealed significantly greater 10 
quantities of cells in the 3-D model of P. aeruginosa monoculture (P<0.001 and 11 
P<0.0001 respectively), as well as the triadic cultures (yeast CFU, P<0.0001, 12 
bacteria CFU, P<0.01, overall viability P<0.01). However, there was some 13 
discrepancy between the two assays with regards to the S. aureus and C. 14 
albicans monocultures. The S. aureus monoculture was shown not to have 15 
significantly higher cells in the 3-D model by conventional culture (P>0.05). 16 
Though, using the viability assay there were significantly (P<0.0001), the 17 
reverse was true of C. albicans monocultures (culture, P<0.0001, viability, 18 
P>0.05).  Molecular analysis also confirmed the number of viable cells within 19 
the 3-D cellulose triadic species model was significantly higher than within the 20 
2-D model (P<0.001). In the 3-D model, there was a significant decrease in the 21 
proportion of S. aureus in the biofilm, in both total and live composition 22 
(P<0.0001), and also a decrease in the live composition of C. albicans 23 
(P<0.05). SEM provided further evidence that irrespective of treatment and 24 
substrate, a significant level of biomass is retained, though notably more upon 25 
the cellulose 3-D matrix.   26 
Further to this, there were also significant differences seen between the two 27 
models after treatment. Both conventional culture and viability assays revealed 28 
that when treated, CHX was less effective in the cellulose matrix model 29 
(P<0.05), with the exception of S. aureus monoculture biofilms where 30 
culturable cells were in fact higher in the 2-D model (P<0.05). PVP-I was 31 
 13 
similarly effective in both models, with higher recalcitrance observed in the 3-D 1 
model for P. aeruginosa (P<0.05) and the bacterial component of the triadic 2 
biofilm (P<0.01). For both mono-species and triadic biofilms, treatments were 3 
also shown to be less effective by live/dead qPCR on the 3-D model, with both 4 
the number of total and live CFEs being significantly increased (P<0.05). 5 
Proportional composition differences were seen after CHX treatment with a 6 
significant decrease in both total and live S. aureus in the biofilm (P<0.0001).  7 
This was also true of PVP-I treatment where all components of the triadic 3-D 8 
cellulose matrix model differed in composition to that of the 2-D model 9 
(P<0.05).  10 
PCA was used to reduce the dimensionality of the viable cell data, and allowed 11 
the data to be plotted along two principal components (Figure 7).  Four distinct 12 
clusters emerged; cluster 1 containing only untreated 2-D model; cluster 2 was 13 
only PVP-I treated 2-D model; cluster 3 contained CHX treated 2-D model and 14 
PVP-I treated 3-D model; cluster 4 containing untreated and CHX treated 3-D 15 
model. These clusters were statistically distinct (P<0.05). Untreated samples 16 
scored higher on PC1 (x axis), this is also true of CHX treated 3-D model, 17 
which were indistinct from their untreated counterpart. Treated samples 18 
generally scored lower on PC1, which is shown by the directionality arrows. 3-19 
D model biofilms generally scored higher on PC2 (y axis), with the exception of 20 
CHX treated 2-D biofilms within cluster 1. Collectively, these data show that 2-21 
D models undergoing treatment can reveal clear effects from antimicrobial 22 
challenge, whereas 3-D models are not subject to the same extent of dynamic 23 
change.   24 
  25 
 14 
Discussion 1 
This study set out to test clinically relevant treatments on a newly developed in 2 
vitro inter-kingdom triadic biofilm model that is more representative of the 3 
physical environment and microbial composition of wounds infections. Based 4 
on the methods employed, we report that our new developed wound model 5 
supports significantly greater quantities of microorganisms, and that this 6 
improved structure reduces the effectiveness of widely used topical 7 
antimicrobial agents. Overall, irrespective of the model used, PVP-I treatment 8 
was generally more effective than CHX in reducing bacterial, fungal and inter-9 
kingdom bioburden. This highlights the need to better understand the biofilm 10 
environment, in particular the importance of mono-, multi-species, or indeed 11 
inter-kingdom biofilms in these infections. 12 
Models that recapitulate complex biofilm related diseases and test 13 
antimicrobial agents are difficult. Moreover, the ways in which these models 14 
are interrogated to generate meaningful data are often flawed. The use of 15 
conventional plate counting is still wide spread despite the inherent bias 16 
towards the outcome antimicrobial challenge. Innovative molecular based 17 
methodologies that analyse viability tend to yield data that is accurate, both 18 
qualitatively and quantitatively. Apparent “complete and efficient killing” 19 
phenomenon demonstrated by conventional microbiological studies of wound 20 
biofilms are not unusual (Hill, et al. 2010, Kart, et al. 2014), including on the 21 
agents tested here on methicillin resistant S. aureus-C. albicans co-cultures 22 
and P. aeruginosa only biofilms (Hoekstra, et al. 2016). However, molecular 23 
viability analysis can often reveal a larger viable population of cells remaining 24 
after treatment (Sherry, et al. 2016). This can be expected, given the nature of 25 
the extracellular matrix combined with viable but non-culturable (VBNC), or 26 
persister cells, which occur naturally within microbial communities.  27 
The novel in vitro interkingdom biofilm model characterised herein consistently 28 
showed higher cell counts and less effectiveness of the topical agents used 29 
compared with biofilms on polystyrene substrates. This may be partially due to 30 
the increased surface area within the cellulose matrix of the novel model. The 31 
comparison against the standardised plastic substrate showed that although 32 
 15 
they are extensively used for many applications (Capita et al. 2014, Kart, et al. 1 
2014, Mottola et al. 2016, Naparstek et al. 2014, Santos et al. 2016), they are 2 
not fully representative of the in vivo situation.  It has been noted previously 3 
that organisms grown with the support of hydrogel matrices are less 4 
susceptible to antimicrobial treatments (Clutterbuck, et al. 2007, Percival, et al. 5 
2007). Within 3-D structures such as these it has previously been noted that 6 
varying metabolic states naturally exist, due to gradients of both oxygen and 7 
nutrients (Rani et al. 2007). These gradients are thought to contribute to 8 
tolerance of antimicrobials in biofilms, which could also contribute to the effects 9 
seen here. This is indeed a limitation of widespread 2-D models. In our study, 10 
this was especially evident with the CHX treatment; which although it 11 
apparently effective in the 2-D model showed only a minimal effect on the 3-D 12 
matrix probably mainly due to the high levels of P. aeruginosa within this model, 13 
which has been found to be resistant to CHX at the wound wash concentration 14 
(Salami et al. 2006). Interestingly, taking a PCA approach we showed that the 15 
untreated and CHX treated cellulose models clustered together, indicating 16 
there is little change in viable composition, which is reinforced by the other 17 
results described herein. While the proportional make-up of the 2-D model was 18 
roughly equally split between the three species, in the 3-D cellulose matrix 19 
model C. albicans and P. aeruginosa dominated. S. aureus was present in the 20 
cellulose matrix model at approximately 2 × log10 lower, which is also reflected 21 
in SEM imaging. Conversely, P. aeruginosa can be observed covering the 3-D 22 
mesh of the untreated cellulose matrix.  23 
Innovative molecular based methodologies that analyse viability tend to yield 24 
data that is accurate, both qualitatively and quantitatively. These have been 25 
used to scrutinise and evaluate the impact of treatment of wound infections, 26 
and are well described. Early wound model studies used qPCR to investigate 27 
compositional changes within their chronic wound biofilm model (Dowd et al. 28 
2009). PCR has previously been criticised for being too sensitive and 29 
overestimating the population when compared to culture techniques, with this 30 
being attributed to eDNA and the presence of dead cells (Castillo et al. 2006, 31 
He and Jiang 2005). As table 2 illustrates, live/dead PCR is the most 32 
expensive technique used in this work. Although qPCR approaches are more 33 
 16 
expensive overall, these methods eliminate the subjectivity and non-specificity 1 
that are associated with conventional microbiology approaches. Moreover, 2 
detrimental interactions produced by P. aeruginosa phenazines have detriment 3 
effects on hyphal growth and viability, effects difficult to decipher with 4 
conventional approaches (Hogan and Kolter 2002). With our approach, 5 
significant differences were demonstrated here in viability, however there was 6 
little difference seen between the biomass of untreated and treated biofilms 7 
(data not shown), which is consistent with other studies where CHX and PVP-I 8 
did not reduce biomass (Sherry et al. 2013, Tote et al. 2010).  9 
No conclusive clinical studies exist which confirm the effectiveness of CHX in 10 
either diabetic foot ulcer or chronic wound infection. A study using a bioreactor 11 
to form an in vitro multi-species biofilm incorporating Klebsiella pneumoniae, P. 12 
aeruginosa, S. aureus and Enterococcus faecalis concluded that the 13 
effectiveness of CHX in controlling a pre-formed biofilm may be limited, 14 
especially on multi-species biofilms (Touzel et al. 2016). 15 
Similarly, definitive clinical studies for PVP-I are lacking. A recent rat model 16 
study found that P. aeruginosa infected wounds irrigated with PVP-I had 17 
reduced bacterial counts both on the wound surface and within the tissue 18 
compared with irrigation with saline (Kanno et al. 2016). However, this model 19 
may be more relevant to skin preparation prior to surgery than to the 20 
management of chronic wounds. A Cochrane review of the use of antiseptics in 21 
pressure ulcers included PVP-I, but not CHX. The study concluded that the 22 
relative effects of systemic and topical antimicrobial treatments on pressure 23 
ulcers are not clear but the evidence was graded from moderate to low quality 24 
(Norman et al. 2015). More useful is the Cochrane review of antibiotics and 25 
antiseptics for venous leg ulcers, which concludes that while some evidence 26 
supports the use of cadexomer iodine more evidence is required before 27 
conclusions can be drawn about the effectiveness of PVP-I or CHX in healing 28 
venous leg ulceration (O’Meara et al. 2013). 29 
 30 
Conclusions 31 
This study highlights importance creating a polymicrobial in vitro biofilm 32 
reflective of the microflora of wounds, containing both fungal and bacterial 33 
components. Representative 3-D biofilm substrates showed an increased 34 
 17 
resistance to antimicrobial wound washes compared to the 2-D plastic surfaces. 1 
Indeed, PCA analysis was clearly able to discern how the models reacted to 2 
different treatments. The necessity of using multiple viability techniques to 3 
analyse different aspects of the biofilm is also recognised. Singular approaches 4 
often only analyse one aspect of the biofilm, but by combining techniques 5 
multiple outputs can be measured and analysed collectively. In practical terms, 6 
this study shows that our ability to influence wound infections of a polymicrobial 7 
and inter-kingdom nature are limited with simple treatments, particularly given 8 
the resilient capacity of complex biofilms and their potential to remain and 9 
seeding reservoirs. Further studies will be important in trying to maximise the 10 
removal and decontamination of complex wound infections, potentially 11 
reducing patient morbidity and mortality. 12 
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Figure 1 – Antimicrobial wound washes exhibit cidal activity against 1 
polymicrobial 2-D biofilms. Bacterial and fungal biofilms were grown as mono (A) 2 
and triadic cultures (B) in a 2-D model, as previously described. Following 3 
development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 4 
24 h. Monospecies (A) and triadic biofilms (B) were assessed by CFU. Viability was 5 
also assessed by the alamarBlue viability assay (C). All testing was carried out in 6 
triplicate, on three separate occasions. Data represents mean ± SD, statistical 7 
analysis compared untreated to treated biofilms (*p<0.05, **p<0.01, ***p<0.001). 8 
#Indicates no cell growth. 9 
 10 
Figure 2 – Molecular analysis demonstrates a significant microbial burden 11 
remains within 2-D biofilms following treatment. Bacterial and fungal monospecies 12 
biofilms were grown in a 2-D model, as previously described. Following development, 13 
biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. 14 
Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated 15 
from standard curves for C. albicans (A), S. aureus (B) and P. aeruginosa (C). Data 16 
represents mean ± SD. * Represents statistical difference in total CFE values and # 17 
represents significant differences between live CFE values (*p<0.05, **p<0.01, 18 
***p<0.001). Data represents CFE values calculated from triplicates carried out on 19 
three separate occasions. 20 
 21 
Figure 3 – Molecular analysis gives insight into cell death in triadic 2-D biofilms, 22 
while SEM reveals complex communities in the triadic model.  Bacterial and 23 
fungal triadic biofilms were grown in a 2-D model, as previously described. Following 24 
development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 25 
24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were 26 
calculated from standard curves for untreated (A), PVP-I (B) and CHX (C). Data 27 
represents percentage composition calculated from CFE values from triplicates 28 
carried out on three separate occasions. SEM, shown in lower panels, was conducted 29 
as described in the methods. Note P. aeruginosa indicated by a solid white arrow, S. 30 
aureus by white arrow head, C. albicans by a black arrow. C. albicans is present in 31 
predominantly hyphae form; the bacteria can be seen attached to the hyphae. Bars 32 
represent 20 µm on lower magnifications (×1000) and 2 µm at higher magnification 33 
(inset, ×6000).  34 
 35 
Figure 4 – PVP-I shows superior killing activity over CHX on 3-D biofilms. 36 
Bacterial and fungal biofilms were grown as mono (A) and triadic cultures (B) in the 3-37 
 24 
D model, as previously described. Following development, biofilms were washed and 1 
treated with PVP-I (10%) or CHX (0.05%) for 24 h. Monospecies (A) and triadic 2 
biofilms (B) were assessed by CFU. Viability was also assessed by the alamarBlue 3 
viability assay (C). All testing was carried out in triplicate, on three separate occasions. 4 
Data represents mean ± SD, statistical analysis compared untreated to treated 5 
biofilms (*p<0.05, **p<0.01, ***p<0.001). #Indicates no cell growth. 6 
 7 
Figure 5 - Molecular analysis demonstrates a significant microbial burden with 8 
limited activity of CHX on 3-D biofilms. Bacterial and fungal monospecies biofilms 9 
were grown in the 3-D model, as previously described. Following development, 10 
biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. 11 
Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated 12 
from standard curves for C. albicans (A), S. aureus (B) and P. aeruginosa (C). Data 13 
represents mean ± SD. * Represents statistical difference in total CFE values and # 14 
represents significant differences between live CFE values (*p<0.05, **p<0.01, 15 
***p<0.001). Data represents CFE values calculated from triplicates carried out on 16 
three separate occasions. 17 
 18 
Figure 6 – Molecular analysis show compositional changes after treatment, 19 
especially with PVP-I, and SEM confirms high levels of growth in the triadic 3-D 20 
model.  Bacterial and fungal triadic biofilms were grown in the 3-D model, as 21 
previously described. Following development, biofilms were washed and treated with 22 
PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-23 
forming equivalents (CFE) were calculated from standard curves for untreated (A), 24 
PVP-I (B) and CHX (C). Data represents percentage composition calculated from CFE 25 
values from triplicates carried out on three separate occasions. SEM, shown in lower 26 
panels, was conducted as described in the methods. Note P. aeruginosa indicated by 27 
a solid white arrow, S. aureus by white arrow head, C. albicans by a black arrow. In 28 
the 3-D model, C. albicans is seen as mostly yeast; here bacteria and yeast are seen 29 
in clusters upon the cellulose matrix. Bars represent 20 µm on lower magnifications 30 
(×1000) and 2 µm at higher magnification (inset, ×6000). 31 
 32 
 33 
Figure 7 – Principal Component Analysis shows little effect of CHX treatment on 34 
cellulose matrix biofilms, whilst treatment of the 2-D model caused a shift to 35 
new clusters. PCA reduces the dimensionality of the data to form clusters. The axes 36 
represent the two principal components of the data which showed the highest 37 
 25 
variance. These cluster patterns showed treatment with CHX does not impact 1 
cellulose matrix biofilms, and PVP-I caused a similar compositional change in the 3-D 2 
model to that of CHX treatment in the 2-D model. ● Untreated 2-D, + Untreated 3-D, ▫ 3 
PVP-I 2-D, ▪ PVP-I 3-D, × CHX 2-D,○ CHX 3-D. 4 
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